Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models
APPswe/Tauvlw

General Information

Posted 30 October 2005

Transgene: Crossed APPSwe (Tg2576) and Tauvlw lines expressing human APP harboring the double Swedish mutation (APPswe) and human 4-repeat tau containing a triple mutation (G272V, P301L and R406W)

Mutation: App Swe, Tau (G272V, P301L and R406W)

Promoter: hamster prion protein gene promoter

Mouse Strain: C57Bl6jxSJL (APPSwe); C57Bl6jxCBA (Tauvlw)

Phenotype

Neuropathological Analysis:

Double transgenic mice showed enhanced amyloid deposition accompanied by neurofibrillary degeneration and overt neuronal loss in selectively vulnerable brain limbic areas. Not only resulted in increased tau phosphorylation but also triggered NFT-like formation in the EC and CA1 regions at 25 months of age. Fivefold higher amyloid burdens in APPsw-tauvlw female mice in comparison to male mice. Co-expression of human mutant APP and tau in the APPsw-tauvlw mouse model enhanced both A͎ and tau pathology and resulted in significant neuronal loss in selective vulnerable brain areas.

Behavior and age of phenotype:

Learning and memory deficits, as measured by the Morris watermaze test, were quite modest at 9 months of age despite incipient amyloid deposits in APPsw-tauvlw and APPsw brains, and significant neuronal loss in the EC in the former. By 16 months, however, both APPsw and APPsw-tauvlw mice showed marked spatial reference memory impairment compared to tauvlw and non-transgenic littermate controls.

Availability

Contact: Teresa Gómez-Isla or J. Avila
Departmento de Neurología
Hospital Santa Creu i Sant Pau
C/Sant Antoni Ma Claret, 167
Barcelona 08025, Spain.

Patent:
European Patent Application No 01936609.5. Model for neurodegenerative disease. JJ Lucas, F Hernandez, J Avila

References

Primary:

M. Perez, E. Ribe, A. Rubio, F. Lim, M.A. Moran, P.G. Ramos, I. Ferrer, M.T. Isla and J. Avila, Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience 130 (2005), pp. 339-347. Abstract.

Associated:

Ribé EM, Pérez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sánchez B, Nieto M, Gómez-Ramos P, Morán MA, Cabodevilla F, Samaranch L, Ortiz L, Pérez A, Ferrer I, Avila J, Gómez-Isla T. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis. 2005 Aug 23. Abstract.

Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci. 2001 Dec;18(6):702-14. Abstract .

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad